Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
7 studies found for:    Eculizumab for Antibody-Mediated Rejection
Show Display Options
Rank Status Study
1 Terminated
Has Results
Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation
Condition: Kidney Transplant
Intervention: Drug: Eculizumab
2 Withdrawn Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation
Condition: Subclinical Acute Antibody-mediated Rejection in Kidney Transplantation
Intervention: Drug: Eculizumab
3 Terminated
Has Results
Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization
Condition: Antibody Mediated Rejection
Intervention: Drug: Eculizumab
4 Terminated Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation
Conditions: Antibody-mediated Rejection;   Humoral Rejection
Interventions: Drug: Eculizumab;   Biological: Immunoglobulin;   Procedure: Plasmapheresis
5 Enrolling by invitation The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
Conditions: Antibody-mediated Rejection;   Hyperacute Rejection of Cardiac Transplant;   Left Ventricular Dysfunction;   Cardiac Allograft Vasculopathy;   Heart Graft Dysfunction
Intervention: Drug: Eculizumab
6 Active, not recruiting Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor
Condition: Stage V Chronic Kidney Disease
Intervention: Drug: Eculizumab
7 Active, not recruiting Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant
Condition: Kidney Transplant
Intervention: Drug: Eculizumab

Study has passed its completion date and status has not been verified in more than two years.